Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon

AIDS Research and Human Retroviruses

Volumn 24, Issue 3, 2008, Pages 393-399

  Laurent, Christian ^a   Bourgeois, Anke ^a   Mpoudi Ngolé, Eitel ^b   Ciaffi, Laura ^c   Kouanfack, Charles ^d   Mougnutou, Rose ^b   Nkoué, Nathalie ^b   Calmy, Alexandra ^c   Koulla Shiro, Sinata ^d   Delaporte, Eric ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b Military Hospital   (Cameroon)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANEMIA; ANTI-HIV AGENTS; CAMEROON; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; KAPLAN-MEIERS ESTIMATE; LAMIVUDINE; MALE; MULTIVARIATE ANALYSIS; NEVIRAPINE; PATIENT COMPLIANCE; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; STAVUDINE; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 41449116953     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0219     Document Type: Article

References (30)

1. World Health Organization: Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: Towards universal access. Recommendations for a public health approach. World Health Organization, Geneva, Switzerland, 2006.
2. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, et al.: The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006;368(9534):505-510.
3. Gazzard B, Bernard AJ, Boffito M, Churchill D, Edwards S, Fisher N, et al.: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2006;7(8):487-503.
4. United States Department of Health and Human Services (DHHS): Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, October 10, 2006. Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf.
5. Colebunders R, Kamya MR, Laurence J, Kambugu A, Byakwaga H, Mwebaze PS, et al.: First-line antiretroviral therapy in Africa - how evidence-based are our recommendations? AIDS Rev 2005;7(3):148-154.
6. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, et al.: Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: Open-label multicentre trial. Lancet 2004;364(9428):29-34.
7. Bourgeois A, Laurent C, Mougnutou R, Nkoué N, Lactuock B, Ciaffi L, et al.: Field assessment of generic antiretroviral drugs: A prospective cohort study in Cameroon. Antiviral Ther 2005;10(2):335-341.
8. Laurent C, Kouanfack C, Koulla-Shiro S, Njoume M, Mawanba Nkene Y, Ciaffi L, et al.: Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine. AIDS 2007;21(6):768-771.
9. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, et al.: Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000;38(11):3919-3925.
10. Laurent C, Diakhaté N, Ngom Gueye NF, Touré MA, Sow PS, Faye MA, et al.: The Senegalese government's highly active antiretroviral therapy initiative: An 18-month follow-up study. AIDS 2002;16(10):1363-1370.
11. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al.: Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004;18(6):887-895.
12. Kumarasamy N, Vallabhaneni S, Cecelia AJ, Yepthomi T, Balakrishnan P, Saghayam S, et al.: Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in Southern India. J Acquir Immune Defic Syndr 2006;41(1):53-58.
13. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, et al.: Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antiviral Ther 2005;10(5):615-624.
14. Ssali F, Stohr W, Munderi P, Reid A, Walker AS, Gibb DM, et al.: Prevalence, incidence and predictors of severe anaemia with zidovudine- containing regimens in African adults with HIV infection within the DART trial. Antiviral Ther 2006;11(6):741-749.
15. Pujari SN, Dravid A, Naik E, Bhagat S, Tash K, Nadler JP, et al.: Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in western India. J Acquir Immune Defic Syndr 2005;39(2):199-202.
16. Forna F, Liechty CA, Solberg P, Asiimwe F, Were W, Mermin J, et al.: Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007;44(4):456-462.
17. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al.: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004;363(9417):1253-1263.
18. Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, et al.: A randomised clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antiviral Ther 2002;7(2):81-90.
19. Moore DA, Benepal T, Portsmouth S, Gill J, and Gazzard BG: Etiology and natural history of neutropenia in human immunodeficiency virus disease: A prospective study. Clin Infect Dis 2001;32(3):469-476.
20. Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Diakhaté N, et al.: Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr 2005;38(1):14-17.
21. Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Touré S, Danel C, et al.: Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire. Antiviral Ther 2003;8(5):385-393.
22. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al.: Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: Comparison between low-income and high-income countries. Lancet 2006;367(9513):817-824.
23. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, et al.: Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: A 7-year cohort study. AIDS 2006;20(8):1181-1189.
24. Lawn SD, Myer L, Orrell C, Bekker LG, and Wood R: Early mortality among adults accessing a community-based antiretroviral service in South Africa: Implications for programme design. AIDS 2005;19(18):2141-2148.
25. Laurent C, Kouanfack C, Vergne L, Tardy M, Zekeng L, Noumsi N, et al.: Antiretroviral drug resistance and routine therapy, Cameroon. Emerg Infect Dis 2006;12(6):1001-1004.
26. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al.: Scaling up of highly active antiretroviral therapy in a rural district of Malawi: An effectiveness assessment. Lancet 2006;367(9519):1335- 1342.
27. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, and Chantratita W: Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007;44(3):447-452.
28. Concato J, Shah N, and Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342(25):1887-1892.
29. Benson K and Hartz AJ: A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342(25):1878-1886.
30. Concato J and Horwitz RI: Beyond randomised versus observational studies. Lancet 2004;363(9422):1660-1661.